Division of Oncology

Medicine & Life Sciences

1. Neoplasms 100%
2. Breast Neoplasms 62%
3. Therapeutics 56%
4. Survival 54%
5. Mutation 52%
6. Drug Therapy 46%
7. Multiple Myeloma 46%
8. Acute Myeloid Leukemia 45%
9. Non-Small Cell Lung Carcinoma 41%
10. Genes 36%
11. T-Lymphocytes 35%
12. Progression-Free Survival 34%
13. Bone Marrow 32%
14. Hematopoietic Stem Cells 30%
15. Genome 30%
16. Leukemia 28%
17. Rituximab 27%
18. Cell Transplantation 27%
19. Non-Hodgkin's Lymphoma 27%
20. Proteins 25%
21. Transplants 25%
22. Immunotherapy 24%
23. Granulocyte Colony-Stimulating Factor 22%
24. Stem Cells 22%
25. Graft vs Host Disease 22%
26. Hodgkin Disease 22%
27. Recurrence 22%
28. Renal Cell Carcinoma 20%
29. Prostatic Neoplasms 20%
30. Mantle-Cell Lymphoma 19%
31. Lymphoma 19%
32. HIV-1 19%
33. Natural Killer Cells 19%
34. Clinical Trials 19%
35. Safety 18%
36. Neoplasm Metastasis 18%
37. High-Throughput Nucleotide Sequencing 18%
38. Lymphoma, Large B-Cell, Diffuse 18%
39. Myelodysplastic Syndromes 18%
40. Radiotherapy 17%
41. Sarcoma 16%
42. DNA 16%
43. Pancreatic Neoplasms 16%
44. Cyclophosphamide 16%
45. Confidence Intervals 16%
46. Allogeneic Cells 16%
47. Growth 16%
48. Adenocarcinoma 16%
49. Lung Neoplasms 16%
50. Cell Line 16%
51. Triple Negative Breast Neoplasms 15%
52. Stem Cell Transplantation 15%
53. Lenalidomide 15%
54. Follicular Lymphoma 15%
55. Mucopolysaccharidosis VII 15%
56. Deltaretrovirus 14%
57. Bortezomib 14%
58. Macrophages 14%
59. Biomarkers 14%
60. Brentuximab Vedotin 14%
61. Guidelines 13%
62. Hematopoiesis 13%
63. Doxorubicin 13%
64. Melanoma 13%
65. plerixafor octahydrochloride 13%
66. Docetaxel 13%
67. Clone Cells 13%
68. B-Cell Lymphoma 13%
69. gemcitabine 13%
70. Apoptosis 12%
71. Gene Expression 12%
72. Hematologic Neoplasms 12%
73. Glioblastoma 12%
74. Paclitaxel 12%
75. Lymphocytes 12%
76. Population 12%
77. Hematopoietic Stem Cell Transplantation 12%
78. Chimeric Antigen Receptors 12%
79. Carboplatin 12%
80. Heterografts 11%
81. Hematopoietic Stem Cell Mobilization 11%
82. Phosphotransferases 11%
83. Maintenance 11%
84. Ligands 11%
85. Human T-lymphotropic virus 1 11%
86. Neutrophils 11%
87. pembrolizumab 11%
88. Cytokines 11%
89. Tissue Donors 11%
90. Cisplatin 11%
91. B-Lymphocytes 11%
92. Bone Marrow Transplantation 11%
93. Carcinoma 10%
94. Protein-Tyrosine Kinases 10%
95. Phenotype 10%
96. Placebos 10%
97. Estrogen Receptors 10%
98. Etoposide 10%
99. Transplantation 10%
100. Proteomics 10%